Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syndax Pharmaceuticals (FRA:1T3) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Syndax Pharmaceuticals Forward PE Ratio Related Terms
Syndax Pharmaceuticals Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Syndax Pharmaceuticals's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syndax Pharmaceuticals Forward PE Ratio Chart
Syndax Pharmaceuticals Annual Data
Trend
Forward PE Ratio
Syndax Pharmaceuticals Quarterly Data
Forward PE Ratio
FRA:1T3 vs FTRE, KARD, STOK: Forward PE Ratio Comparison
For the Biotechnology subindustry, Syndax Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syndax Pharmaceuticals Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Syndax Pharmaceuticals's Forward PE Ratio falls into.
Syndax Pharmaceuticals Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Syndax Pharmaceuticals (FRA:1T3) has a Forward PE Ratio of 0.00 as of Aug. 10, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Syndax Pharmaceuticals and its competitors. According to the industry distribution chart, Syndax Pharmaceuticals ranks #999999 out of 353 companies in the Biotechnology industry.
Is Syndax Pharmaceuticals' Forward PE Ratio too high?
Syndax Pharmaceuticals' current Forward PE Ratio is 0.00. Based on the distribution chart, Syndax Pharmaceuticals ranks #999999 out of 353 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Syndax Pharmaceuticals has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Syndax Pharmaceuticals' Forward PE Ratio compare to FTRE and KARD?
According to the Biotechnology industry distribution chart, Syndax Pharmaceuticals ranks #999999 out of 353 companies for Forward PE Ratio. This places Syndax Pharmaceuticals in the lower half of its industry. The industry median Forward PE Ratio is 22.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.32, based on 353 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Syndax Pharmaceuticals and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syndax Pharmaceuticals's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syndax Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Syndax Pharmaceuticals (FRA:1T3) is currently considered Possible Value Trap. The stock's GF Value™ is €665.27, compared to a current price of €17.37 — trading 97.4% below its estimated fair value. The current Forward PE Ratio is 0.00. Syndax Pharmaceuticals' overall GF Score™ is 27/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Syndax Pharmaceuticals (FRA:1T3), the current Forward PE Ratio is 0.00 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syndax Pharmaceuticals (FRA:1T3) Overvalued in 2026?
Based on GuruFocus' analysis, Syndax Pharmaceuticals stock appears to be undervalued.
The current stock price of €17.37 is trading 97.4% below its estimated GF Value™ of €665.27.
GuruFocus considers Syndax Pharmaceuticals to be Possible Value Trap.
Key valuation signals for FRA:1T3:
Forward PE Ratio: 0.00
GF Value™: €665.27 vs. price of €17.37 (97.4% below fair value)
No single metric tells the full story. See the FRA:1T3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
27GF Score
Get the complete analysis for FRA:1T3
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1T3 has been successfully added to your 
